Display options
Cite
Nathwani R, Kockerling D, Mullish BH, et al. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline Gastroenterol. 2021;13(1):86-88doi: 10.1136/flgastro-2021-101818.
Nathwani, R., Kockerling, D., Mullish, B. H., Cole, A., Lemoine, M., Antoniades, C. G., Thursz, M. R., & Dhar, A. (2022). Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline gastroenterology, 13(1), 86-88. https://doi.org/10.1136/flgastro-2021-101818
Nathwani, Rooshi, et al. "Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections." Frontline gastroenterology vol. 13,1 (2022): 86-88. doi: https://doi.org/10.1136/flgastro-2021-101818
Nathwani R, Kockerling D, Mullish BH, Cole A, Lemoine M, Antoniades CG, Thursz MR, Dhar A. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline Gastroenterol. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. eCollection 2022. PMID: 34970431; PMCID: PMC8666853.
Copy Download .nbib Format: NLM
Share it on

Frontline Gastroenterol. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. eCollection 2022.

Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections.

Frontline gastroenterology

Rooshi Nathwani, David Kockerling, Benjamin H Mullish, Alexander Cole, Maud Lemoine, Charalambos Gustav Antoniades, Mark R Thursz, Ameet Dhar

Affiliations

  1. Division of Digestive Diseases, Imperial College London, London, UK.
  2. Department of Metabolism, Digestion and Reproduction, Imperial College Healthcare NHS Trust, London, UK.

PMID: 34970431 PMCID: PMC8666853 DOI: 10.1136/flgastro-2021-101818

[No abstract available.]

Keywords: bacterial infection; cirrhosis; portal hypertension

Conflict of interest statement

Competing interests: None declared.

Publication Types